Improving survival from Acute myeloid leukaemia (AML) with new therapies

Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults. Despite advancements in treatments, the five year survival rate remains at a dismal 24%, and the development of drug resistance is common. Therefore, new anti-cancer targets need to be identified to improve the outcomes for AML patients. One new target is a molecule involved in the growth and survival of leukaemia cells.  The goal of this project is to develop a new therapy for acute myeloid leukaemia that improves survival, without increasing side effects and toxicity associated with treatment.

Research Area 
Project type 
Project Grant
Year of funding